DE69504305D1 - Inhibitoren der menschlichen leukozyten-elastase (hle), sie enthaltende pharmazeutische zusammensetzungen und verfahren zur verwendung - Google Patents

Inhibitoren der menschlichen leukozyten-elastase (hle), sie enthaltende pharmazeutische zusammensetzungen und verfahren zur verwendung

Info

Publication number
DE69504305D1
DE69504305D1 DE69504305T DE69504305T DE69504305D1 DE 69504305 D1 DE69504305 D1 DE 69504305D1 DE 69504305 T DE69504305 T DE 69504305T DE 69504305 T DE69504305 T DE 69504305T DE 69504305 D1 DE69504305 D1 DE 69504305D1
Authority
DE
Germany
Prior art keywords
hle
inhibitors
pharmaceutical compositions
compositions containing
human leukocyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69504305T
Other languages
English (en)
Other versions
DE69504305T2 (de
Inventor
Charles Hiebert
Alan Laibelman
Kenneth Ryan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SRI International Inc
Original Assignee
SRI International Inc
Stanford Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SRI International Inc, Stanford Research Institute filed Critical SRI International Inc
Application granted granted Critical
Publication of DE69504305D1 publication Critical patent/DE69504305D1/de
Publication of DE69504305T2 publication Critical patent/DE69504305T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
    • C07D265/22—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
    • C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
DE69504305T 1994-01-27 1995-01-20 Inhibitoren der menschlichen leukozyten-elastase (hle), sie enthaltende pharmazeutische zusammensetzungen und verfahren zur verwendung Expired - Fee Related DE69504305T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/188,579 US5428021A (en) 1994-01-27 1994-01-27 Human leukocyte elastase (HLE) inhibitors, and related pharmaceutical compositions and methods of use
PCT/US1995/000885 WO1995020581A1 (en) 1994-01-27 1995-01-20 Novel human leukocyte elastase (hle) inhibitors, and related pharmaceutical compositions and methods of use

Publications (2)

Publication Number Publication Date
DE69504305D1 true DE69504305D1 (de) 1998-10-01
DE69504305T2 DE69504305T2 (de) 1999-01-07

Family

ID=22693738

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69504305T Expired - Fee Related DE69504305T2 (de) 1994-01-27 1995-01-20 Inhibitoren der menschlichen leukozyten-elastase (hle), sie enthaltende pharmazeutische zusammensetzungen und verfahren zur verwendung

Country Status (7)

Country Link
US (1) US5428021A (de)
EP (1) EP0741715B1 (de)
JP (1) JPH09508388A (de)
KR (1) KR970700664A (de)
CA (1) CA2182203A1 (de)
DE (1) DE69504305T2 (de)
WO (1) WO1995020581A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985872A (en) * 1995-05-24 1999-11-16 G.D. Searle & Co. 2-amino-benzoxazinones for the treatment of viral infections
US6504028B2 (en) * 2000-07-11 2003-01-07 The Procter & Gamble Co. Process for preparing benzoxazin-4-one polymer conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657893A (en) * 1984-05-09 1987-04-14 Syntex (U.S.A.) Inc. 4H-3,1-benzoxazin-4-ones and related compounds and use as enzyme inhibitors
CA1309556C (en) * 1987-06-09 1992-10-27 Masayuki Kokubo 4h-3,1-benzoxazin-4-one compounds and pharmaceutical composition thereoffor the inhibition of serine proteases
JP2685648B2 (ja) * 1990-02-15 1997-12-03 帝人株式会社 ４ｈ−３．１−ベンズオキサジン−４−オン化合物

Also Published As

Publication number Publication date
DE69504305T2 (de) 1999-01-07
JPH09508388A (ja) 1997-08-26
WO1995020581A1 (en) 1995-08-03
EP0741715A1 (de) 1996-11-13
CA2182203A1 (en) 1995-08-03
EP0741715B1 (de) 1998-08-26
US5428021A (en) 1995-06-27
KR970700664A (ko) 1997-02-12

Similar Documents

Publication Publication Date Title
DE69602624D1 (de) Instrumentation zur Verwendung in der orthopädischen Chirurgie
ATE348607T1 (de) Verfahren und pharmazeutische zusammensetzung zur regelung der lipidkonzentration
DE69633835D1 (de) Als ampulle dienende spritze und spritze zur blutentnahme
ATE181824T1 (de) Mittel zur feuchthaltung von gewebe und verfahren
DE69519235D1 (de) Hämorrhoidenzusammensetzungen und verfahren zur verwendung
ATE376543T1 (de) Indazol-verbindungen und pharmazeutische zusammensetzungen zur hemmung von proteinkinasen und verfahren zu ihrer verwendung
DE69635711D1 (de) Nachweissystem und verfahren zur quantativen feststellung von zahnkaries
DE69631157D1 (de) Pharmazeutische Zubereitung zur Verwendung in der Behandlung von Diabetes
DE69307220D1 (de) System zur Fixierung und Wiederherstellung eines Wirbels
DE69605710D1 (de) Vorfuellbare Spritze und Stopfer dafür
DE69305500D1 (de) Zahnersatz und kleber und verfahren zur verwendung
FR2741622B1 (fr) Composes photo-initiateurs, composition les contenant, leur utilisation et procedes les utilisant
DE69331176D1 (de) Knochenzement und Verfahren zu seiner Herstellung
DE19681227T1 (de) Verfahren und System zum Sterilisieren von medizinischen Instrumenten
DE69233474D1 (de) Pharmazeutische Zusammensetzung enthaltend S-Nitrosoimmunoglobuline und Verwendung davon
ATE216564T1 (de) Therapeutische nahrungsmittelzusammensetzung und verfahren zur verminderung der schwankungen der blutzuckerstand
DE69828571D1 (de) Blutfiltersatz und zugehöriges Verfahren zur Gewinnung von Blutkomponenten
DE69521206D1 (de) Quinoa saponin zubereitungen und verfahren zur verwendung
DE69604712D1 (de) Alpha-Aluminiumoxid und Verfahren zur dessen Herstellung
FI973211A (fi) Ihmisen leukosyyttielastaasin inhibiittoreina hyödylliset proliinijohdannaiset
ATE204177T1 (de) Verwendung von substanz p antagonist im pharmazeutischer zusammensetzung
DE4498692T1 (de) Pharmazeutische Kompositionen zum Vorbeugen und Heilen von Krebserkrankungen und Verfahren zu ihrer Herstellung
ATE141803T1 (de) Verfahren zur konservierung ophthalmischer lösungen und zusammensetzungen dafür
ATE113274T1 (de) Alkylaminalkoxyphenyl-derivate, verfahren zur verwendung und sie enthaltende zusammensetzungen.
DE69637830D1 (de) Mittel und verfahren zur verhinderung der durch nichtsteroidale antiinflammatorische arzneistoffe verursachten toxizität

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee